Stent Tek, a medical device company that is developing a minimally invasive catheter system for dialysis patients, announced today it has successfully closed a Series A funding round with investments from two institutional investors.
MedGenomeGenomics research and diagnostics company MedGenome said today that it closed a $30 million Series C round led by Sequoia India and Sofina. Zodius Capital, the co-founder & former CEO of Infosys, Kris Gopalakrishnan, and former Cognizant CEO Lakshmi Narayanan also participated in the round.
Resonetics announced today its acquisition of Aduro Laser, an emerging leader in laser processing of tubular components for the medical device industry.
Collaboration on an oncology drug discovery program was inked between Takeda Pharmaceutical, through its subsidiary Millennium Pharmaceuticals, and Molecular Templates.
Merck Ventures has become the latest group to invest in Macrophage Pharma and take a position on the UK biotech’s board of directors.
A distribution agreement for Align’s iTero Element intraoral scanning system has been signed between Patterson Dental, a business unit of Patterson Companies, and Align Technology.
GlaxoSmithKline is taking some heat at home over questions about global shortages of its and Merck’s hepatitis B vaccine that triggered rationing in the U.K., although GSK’s supplies to the much larger U.S. market seem to be unaffected.
NeoSync has announced the completion of its Series D financing round, which included investment from Valiance Life Science Investments, as well as its original investor base totaling $13m.
Vascular focused device developer VentureMed said today it raised $15 million in a Series B round.
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.